Answers are grounded in this paper and cite their sources.
B cells combine antigen-specific recognition, antigen presentation, antibody secretion, and differentiation into long-lived plasma cells, making them attractive candidates for therapeutic engineering. Advances in genome editing and synthetic biology have enabled therapeutic protein and antibody production, programmable antigen recognition, and controlled cellular responses. This review examines the biological basis of engineered B cell platforms, major genetic and functional engineering strategies, therapeutic applications, preclinical evidence, and barriers to translation. Preclinical studies have demonstrated sustained production of therapeutic proteins and antibodies, antibody-mediated antitumor effects, and antigen presentation that can activate antigen-specific T cell responses. These findings support using engineered B cells as durable sources of therapeutic molecules and as active participants in immune regulation. However, the field remains predominantly preclinical. Reliable control of editing efficiency, differentiation, persistence, therapeutic output, manufacturing, genomic safety, and long-term function will be required before clinical use. Engineered B cells therefore represent a promising therapeutic platform, but their efficacy and safety in patients remain to be established.
No takes yet. Share an insight, caveat, or question.
Siddiqui et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: